Par Pharmaceutical Begins Shipment of Generic Atacand HCT®

          Par Pharmaceutical Begins Shipment of Generic Atacand HCT®

PR Newswire

WOODCLIFF LAKE, N.J., Dec. 5, 2012

WOODCLIFF LAKE, N.J., Dec. 5, 2012 /PRNewswire/ -- Par Pharmaceutical
Companies, Inc. today announced that its Par Pharmaceutical, Inc. operating
subsidiary has entered into an exclusive U.S. supply and distribution
agreement with AstraZeneca to distribute the authorized generic version of
AstraZeneca's Atacand HCT^® (candesartan cilexetil/hydrochlorothiazide). Par
has begun shipping 16/12.5 mg, 32/12.5 mg and 32/25 mg strengths of
candesartan cilexetil/ hydrochlorothiazide tablets. According to IMS Health
data, annual U.S. sales of Atacand HCT^® are approximately $61 million.

Important Information about Candesartan Cilexetil/Hydrochlorothiazide Tablets
Candesartan cilexetil/hydrochlorothiazide combines an angiotensin II receptor
blocker and a diuretic, hydrochlorothiazide, and is indicated for the
treatment of hypertension. This fixed dose combination is not indicated for
initial therapy.

Candesartan cilexetil/hydrochlorothiazide is contraindicated in patients who
are hypersensitive to any component of the product. Because of the
hydrochlorothiazide component, candesartan cilexetil/hydrochlorothiazide is
contraindicated in patients with anuria or hypersensitivity to other
sulfonamide-derived drugs.

A black box warning is associated with this product regarding fetal toxicity.
When pregnancy is detected, candesartan cilexetil/hydrochlorothiazide should
be discontinued as soon as possible. Drugs that act directly on the
rennin-angiotensin system can cause injury and death to the developing fetus.
Refer to full prescribing information for complete boxed warning.

About Par Pharmaceutical Companies, Inc.
Par Pharmaceutical Companies, Inc. is a privately held, U.S.-based specialty
pharmaceutical company that develops, manufactures and markets high
barrier-to-entry generic drugs and niche, innovative proprietary
pharmaceuticals through its wholly-owned subsidiary's two operating divisions,
Par Pharmaceutical and Strativa Pharmaceuticals. For press release and other
company information, visit www.parpharm.com.

SOURCE Par Pharmaceutical Companies, Inc.

Website: http://www.parpharm.com
Contact: Stephen Mock, Par Pharmaceutical Companies, Inc., +1-201-802-4033